clinical trial · NCT02653976
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Solasia Pharma K.K.·phase2·completed·n = 67
Peripheral T-Cell LymphomaSP-02L (darinaparsin for injection)
brief summary
This study is a phase 2 multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of SP-02L monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma.
started
Mar 25, 2016
primary completion
Oct 11, 2020
completion
Jun 17, 2021
last updated
Jan 26, 2024
official title
Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol